Defence Therapeutics has named Dr. Amie Phinney as its new President and CEO, effective August 1, 2026, with founder Sébastien Plouffe moving to Executive Chairman. Dr. Phinney brings over 20 years of pharmaceutical and biotech leadership experience and has been instrumental in advancing the company's Accum® drug delivery technology. This leadership change aims to accelerate the development of Defence's therapeutic pipeline and expand strategic partnerships, positioning the company for growth in precision oncology treatments. The company also granted stock options to Dr. Phinney and key executives to align incentives with long-term success.
The global Gate Driver Integrated Circuit (IC) market is projected to grow from USD 1.76 billion in 2025 to USD 2.91 billion by 2035, at a CAGR of 5.19%. Growth is fueled by rising electric vehicle adoption, renewable energy infrastructure, and advan...
BTS Group AB, a global consultancy specializing in strategy execution and people development, will present its Q2 2026 interim report on August 14, 2026, at 15:00 CEST. CEO Jessica Skon will lead the presentation, which investors and analysts can fol...
BTS Group AB, a global consulting firm specializing in strategy execution and leadership development, will hold its Q2 2026 financial report presentation on August 14, 2026, at 15:00 CET. CEO Jessica Skon will lead the presentation, which will be con...
Logitech G is organizing its flagship gaming event, Logitech G PLAY 2026, in Warsaw on September 22-23 at EXPO XXI. The event features The House of G, a 3,000-square-meter gaming playground with interactive zones including sim-racing setups, streamin...
French retail giant Carrefour will present its brand extension and licensing strategies during an exclusive keynote panel at Brand Licensing Europe 2026, held from October 6-8 in London. The session will feature Carrefour's Director of Toys & Leisure...
